We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+4.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$8.02B
AUM Growth
+$201M
Cap. Flow
-$89M
Cap. Flow %
-1.11%
Top 10 Hldgs %
19.81%
Holding
867
New
76
Increased
308
Reduced
302
Closed
63

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.8M
2
PG icon
Procter & Gamble
PG
+$24.6M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$23.6M
4
KEYS icon
Keysight
KEYS
+$23.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$21.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$46.5M
2
XOM icon
ExxonMobil
XOM
+$36.6M
3
GG
Goldcorp Inc
GG
+$24.9M
4
DIS icon
Walt Disney
DIS
+$23.8M
5
NAVG
Navigators Group Inc
NAVG
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 33.16%
2 Technology 16.87%
3 Financials 10.38%
4 Consumer Discretionary 9.09%
5 Communication Services 7.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PE
826
DELISTED
PARSLEY ENERGY INC
PE
– –
-12,372
Closed -$239K
S
827
DELISTED
Sprint Corporation
S
– –
-371,048
Closed -$2.1M
DOVA
828
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-233,200
Closed -$2.07M
INSY
829
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-18,500
Closed -$85K
LXFT
830
DELISTED
Luxoft Holding, Inc.
LXFT
– –
-127,300
Closed -$7.47M
BMS
831
DELISTED
Bemis
BMS
– –
-11,000
Closed -$610K
NITE
832
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
– –
-97,043
Closed -$2.46M
TVPT
833
DELISTED
Travelport Worldwide Limited
TVPT
– –
-264,697
Closed -$4.16M
MRT
834
DELISTED
MedEquities Realty Trust, Inc.
MRT
– –
-422,814
Closed -$4.71M
HIFR
835
DELISTED
InfraREIT, Inc.
HIFR
– –
-131,885
Closed -$2.77M
ULTI
836
DELISTED
Ultimate Software Group Inc
ULTI
– –
-15,200
Closed -$5.02M
USG
837
DELISTED
Usg
USG
– –
-371,000
Closed -$16.1M
BHBK
838
DELISTED
Blue Hills Bancorp, Inc.
BHBK
– –
-215,007
Closed -$5.14M
NAVG
839
DELISTED
Navigators Group Inc
NAVG
– –
-273,901
Closed -$19.1M
OMED
840
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-380,000
Closed -$395K
GG
841
DELISTED
Goldcorp Inc
GG
– –
-2,173,515
Closed -$24.9M
30 31 32 33
34

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2019 Portfolio in Review

As of Q2 2019, Candriam SCA held 867 positions worth $8.02B, up 2.6% from $7.82B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Candriam SCA's Q2 2019 filing shows 76 new, 308 increased, 302 reduced and 63 closed positions. Its largest new stake was Total System Services, Inc.: 112,342 shares worth $14.3M. The largest sale was Celgene Corp, an estimated $46.5M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q2 2019 buy was Total System Services, Inc.: 112,342 shares worth $14.3M.
  • Candriam SCA added most to Vertex Pharmaceuticals in Q2 2019, an estimated $48.8M increase.
  • Candriam SCA's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $46.5M.
  • Candriam SCA fully exited Goldcorp Inc in Q2 2019, selling an estimated $24.9M.
  • Candriam SCA's ten largest holdings make up 20% of its $8.02B portfolio in Q2 2019.
  • Candriam SCA opened 76 new positions and closed 63 in Q2 2019.
  • Candriam SCA's portfolio value rose 2.6% quarter-over-quarter to $8.02B.

Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.